JP2017505789A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505789A5 JP2017505789A5 JP2016551215A JP2016551215A JP2017505789A5 JP 2017505789 A5 JP2017505789 A5 JP 2017505789A5 JP 2016551215 A JP2016551215 A JP 2016551215A JP 2016551215 A JP2016551215 A JP 2016551215A JP 2017505789 A5 JP2017505789 A5 JP 2017505789A5
- Authority
- JP
- Japan
- Prior art keywords
- aerosol formulation
- micrograms
- sirolimus
- particles
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 42
- 238000009472 formulation Methods 0.000 claims description 31
- 239000002245 particle Substances 0.000 claims description 25
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 22
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 22
- 229960002930 sirolimus Drugs 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 13
- 239000000443 aerosol Substances 0.000 claims description 12
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 238000010902 jet-milling Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 229940112141 dry powder inhaler Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 4
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000011888 foil Substances 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920003023 plastic Polymers 0.000 claims 2
- 239000004033 plastic Substances 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 238000007517 polishing process Methods 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003380 propellant Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 1
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461938282P | 2014-02-11 | 2014-02-11 | |
| US61/938,282 | 2014-02-11 | ||
| US201462060970P | 2014-10-07 | 2014-10-07 | |
| US62/060,970 | 2014-10-07 | ||
| PCT/US2015/015266 WO2015123219A1 (en) | 2014-02-11 | 2015-02-10 | Rapamycin for the treatment of lymphangioleiomyomatosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505789A JP2017505789A (ja) | 2017-02-23 |
| JP2017505789A5 true JP2017505789A5 (enExample) | 2020-01-23 |
Family
ID=52595442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551215A Pending JP2017505789A (ja) | 2014-02-11 | 2015-02-10 | リンパ脈管筋腫症の治療のためのラパマイシン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150265582A1 (enExample) |
| EP (1) | EP3104891A1 (enExample) |
| JP (1) | JP2017505789A (enExample) |
| KR (1) | KR20160120739A (enExample) |
| CN (1) | CN106573067A (enExample) |
| AU (1) | AU2015217349A1 (enExample) |
| BR (1) | BR112016018365A2 (enExample) |
| CA (1) | CA2939342A1 (enExample) |
| IL (1) | IL247155A0 (enExample) |
| MX (1) | MX2016010373A (enExample) |
| RU (1) | RU2016136348A (enExample) |
| WO (1) | WO2015123219A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117035A1 (en) | 2013-01-24 | 2014-07-31 | Transderm, Inc. | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS |
| CA2926719C (en) | 2013-10-08 | 2020-11-24 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| RS64482B1 (sr) | 2014-04-04 | 2023-09-29 | Ai Therapeutics Inc | Inhalaciona formulacija rapamicina za lečenje stanja povezanih sa starenjem |
| AU2015330905B2 (en) | 2014-10-07 | 2021-02-25 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| MA40910A (fr) * | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) * | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| US10383860B2 (en) * | 2015-07-28 | 2019-08-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same |
| US11224594B2 (en) * | 2015-09-16 | 2022-01-18 | Philip Morris Products S.A. | Nicotine formulations and methods of making and using the same |
| GB201611639D0 (en) | 2016-07-04 | 2016-08-17 | Ockham Biotech Ltd | Delivery device and formulation |
| CA3049402A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| PT110585B (pt) * | 2018-02-22 | 2021-04-22 | Hovione Farmaciencia Sa | Processo de produção contínua de partículas compreendendo secagem por atomização com preparação contínua da solução de atomização |
| US10350226B1 (en) * | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| EP4216968A4 (en) * | 2020-09-25 | 2024-10-16 | University of Cincinnati | METHOD OF PLEURODESIS AND ADMINISTRATION OF DRUGS TO THE LUNG AND PLEURAL SPACE |
| WO2022170027A1 (en) * | 2021-02-04 | 2022-08-11 | Edenbridge Pharmaceuticals, LLC | Inhaled ivermectin |
| CN114755421B (zh) * | 2022-04-07 | 2025-07-18 | 华中科技大学同济医学院附属同济医院 | 淋巴管平滑肌瘤病的蛋白质生物标志物及应用 |
| CN118615239B (zh) * | 2024-06-17 | 2025-07-22 | 明思未来(北京)科技发展有限公司 | 一种依维莫司眼局部给药制剂 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2517482A (en) * | 1949-04-09 | 1950-08-01 | Sharp & Dohme Inc | Inhaler |
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| AU688782B2 (en) * | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
| US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US6451784B1 (en) | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
| NZ336381A (en) | 1996-12-30 | 2000-11-24 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US20040039047A1 (en) | 1998-08-11 | 2004-02-26 | Mark Zamoyski | Compositions and methods for treating lung cancers |
| US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| WO2003015707A2 (en) | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
| WO2003015521A1 (en) | 2001-08-20 | 2003-02-27 | Transave, Inc. | Treatment of cancers by inhalation of stable platinum-containing formulations |
| WO2003099362A1 (en) | 2002-05-20 | 2003-12-04 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| AR050374A1 (es) * | 2004-08-20 | 2006-10-18 | Wyeth Corp | Forma polimorfica de rafampicina |
| KR20070083839A (ko) | 2004-09-29 | 2007-08-24 | 코디스 코포레이션 | 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태 |
| US20080275076A1 (en) | 2005-03-08 | 2008-11-06 | Per Holm | Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof |
| WO2006101972A2 (en) * | 2005-03-17 | 2006-09-28 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
| CN1883474A (zh) * | 2005-06-22 | 2006-12-27 | 华北制药集团新药研究开发有限责任公司 | 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物 |
| EP1962819A1 (en) * | 2005-12-20 | 2008-09-03 | Wyeth | Control of cci-779 dosage form stability through control of drug substance impurities |
| PT1983984T (pt) | 2006-02-02 | 2018-06-14 | Novartis Ag | Tratamento da esclerosa tuberosa |
| EP1938800A1 (en) * | 2006-12-06 | 2008-07-02 | Ranbaxy Laboratories Limited | Sirolimus nanodispersion |
| EP1952807A1 (en) | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
| CA2686736A1 (en) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
| CN102292072A (zh) * | 2009-01-26 | 2011-12-21 | 特瓦制药工业有限公司 | 用微粒包衣载体的方法 |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| US9248110B2 (en) * | 2010-03-18 | 2016-02-02 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis |
| PT105058B (pt) | 2010-04-21 | 2013-04-17 | Hovione Farmaciencia S A | Processo para processamento de partículas de ingredientes activos farmacêuticos |
| WO2011163600A2 (en) | 2010-06-25 | 2011-12-29 | Apt Pharmaceuticals, Inc. | Tacrolimus compositions for aerosol administration |
| JP2013538830A (ja) * | 2010-09-27 | 2013-10-17 | マイクロドース セラピューテクス，インコーポレイテッド | 吸入を用いる疾患治療のための方法及び組成物 |
| EP3721784B1 (en) * | 2013-03-28 | 2023-12-20 | EndoChoice, Inc. | Compact multi-viewing element endoscope system |
| CA2926719C (en) * | 2013-10-08 | 2020-11-24 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
-
2015
- 2015-02-10 AU AU2015217349A patent/AU2015217349A1/en not_active Abandoned
- 2015-02-10 KR KR1020167023793A patent/KR20160120739A/ko not_active Withdrawn
- 2015-02-10 WO PCT/US2015/015266 patent/WO2015123219A1/en not_active Ceased
- 2015-02-10 JP JP2016551215A patent/JP2017505789A/ja active Pending
- 2015-02-10 BR BR112016018365A patent/BR112016018365A2/pt not_active Application Discontinuation
- 2015-02-10 EP EP15706986.5A patent/EP3104891A1/en not_active Withdrawn
- 2015-02-10 CN CN201580019126.6A patent/CN106573067A/zh active Pending
- 2015-02-10 RU RU2016136348A patent/RU2016136348A/ru not_active Application Discontinuation
- 2015-02-10 MX MX2016010373A patent/MX2016010373A/es unknown
- 2015-02-10 CA CA2939342A patent/CA2939342A1/en not_active Abandoned
- 2015-02-10 US US14/618,621 patent/US20150265582A1/en not_active Abandoned
-
2016
- 2016-08-07 IL IL247155A patent/IL247155A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505789A5 (enExample) | ||
| AU2022287624B2 (en) | Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation | |
| CA2319100C (en) | Microparticle inhalation formulations | |
| JP3210012B2 (ja) | 医薬品 | |
| CN105193773A (zh) | 活性剂的呼吸递送 | |
| JP2002512183A (ja) | 医薬用エアゾール製剤 | |
| CN103687483A (zh) | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 | |
| JP2015512925A (ja) | 集合粒子 | |
| Yang et al. | The effects of surface morphology on the aerosol performance of spray-dried particles within HFA 134a based metered dose formulations | |
| US10517828B2 (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| CN105101955A (zh) | 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物 | |
| Sinswat et al. | Nebulization of nanoparticulate amorphous or crystalline tacrolimus–single-dose pharmacokinetics study in mice | |
| WO2005055985A1 (en) | Metered dose inhalation preparations of therapeutic drugs | |
| CN108463213B (zh) | 可吸入扎鲁司特颗粒的制备 | |
| Li et al. | Novel pMDI formulations for pulmonary delivery of proteins | |
| RS58746B2 (sr) | Kompozicije proleka aripiprazola | |
| Paul et al. | Potentials and challenges of Levodopa particle formulation for treatment of Parkinson’s disease through intranasal and pulmonary delivery | |
| JP7157830B2 (ja) | アリピプラゾールプロドラッグ組成物 | |
| Dhahir et al. | Dry powder inhalers: main characteristics, classifications and novel drug delivery systems review | |
| Sallam | Recent advances in the formulation development of inhalational dosage forms | |
| Moon et al. | Thin-Film Freeze-Drying Process for Versatile Particles for Inhalation Drug Delivery | |
| WO2024026412A1 (en) | Thin film freezing methods and compositions formulated from dispersed active agents | |
| KR20240172320A (ko) | 흡입용 이트라코나졸 함유 건조분말 제형 및 이의 제조방법 | |
| HK40049829B (zh) | 阿立哌唑前体药物组合物 | |
| Sonvico et al. | Nanostructures for Overcoming the Pulmonary Barrier: Drug Delivery Strategies |